NCT00035061View on ClinicalTrials.gov

A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium

PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

Not specified

Conditions

Urologic NeoplasmsMetastases, Neoplasm

Interventions

DRUG

pemetrexed

Trial Locations (20)

Unknown

Los Angeles

Palo Alto

Boca Raton

Tampa

Decatur

Indianapolis

Lafayette

Muncie

South Bend

Lenexa

Saint Mathews

Boston

Omaha

Cleveland

Philadelphia

Pittsburgh

Nashville

Fort Worth

Houston

Seattle

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT00035061 - A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium | Biotech Hunter | Biotech Hunter